| Name | Title | Contact Details |
|---|
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The IlluminOss System utilizes a light-curable polymer, contained within an expandable balloon catheter to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in the EU under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Flare Capital Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
The pioneering team at Surefire Medical is inventing the future for cancer care. We develop advanced liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries paired with new, precise technology arm physicians to harness infusion pressure and work with the body’s natural flow, targeting tumors with superior accuracy, control and protection. Our founders, a biomedical engineer and an Interventional Radiologist, established Surefire Medical to revolutionize cancer treatment. Our inventive device technology is designed by and for the IR community by a Colorado-based team of physicians, engineers and researchers. We seek clinical discoveries and create new technologies with one goal in mind: to deliver improved outcomes for cancer patients and their families.
Corinth MedTech, a small startup company located in Cupertino, CA, and founded in 2014, developed a bipolar transurethral and transcervical resection system intended for endoscopically controlled tissue removal for male patients diagnosed with benign prostatic hyperplasia (BPH), and female patients diagnosed with Abnormal Uterine Bleeding (AUB), fibroids and/or polyps requiring Hysteroscopic tissue removal.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.
Avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries.